Skip to content

Integra LifeSciences to Present at Three Conferences in February


<< Back

Press Release

Feb 2, 2012

Integra LifeSciences to Present at Three Conferences in February

PLAINSBORO, N.J., Feb. 2, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at the following conferences this month:

  • At 2:00 PM PT on Tuesday, February 7, 2012, Mr. Brian Larkin, President, Global Spine & Orthobiologics and Head of Strategic Development of Integra, will present at the Canaccord Genuity Musculoskeletal Conference in San Francisco, CA. A link to the webcast for this presentation will be posted on our website on the Investor Relations section at www.integralife.com.
  • At 9:00 AM ET on Tuesday, February 28, 2012, Mr. Peter Arduini, President and Chief Executive Officer of Integra, will present at the RBC Capital Markets' Global Healthcare Conference in New York City. A link to the webcast for this presentation will be posted on our website on the Investor Relations section at www.integralife.com.
  • At 2:00 PM ET on Tuesday, February 28, 2012, Mr. Arduini will also present at the Citi Global Health Care Conference in New York City. This presentation will not be webcast.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as of the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Integra LifeSciences Holdings Corporation

         

         John B. Henneman, III

         Executive Vice President, Chief Financial Officer

         (609) 275-0500

         jack.henneman@integralife.com

         

         Investor Relations:

         Angela Steinway

         (609) 936-2268

         angela.steinway@integralife.com